Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imetelstat versus placebo in transfusion-dependent lower-risk myelodysplastic syndrome after ESA failure
NL-OMON54841Phase 3Recruiting
- Sponsor
- Geron Corporation
- Start
- Dec 2015
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of imetelstat in myelodysplastic syndrome (MDS), sponsored by Geron Corporation. Started Dec 2015; status: recruiting.
02
Drugs
imetelstat
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NL-OMON54841.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54841.